This study investigates the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) to pancreatic cancer.
The study evaluates how IPMN progresses to malignancy and examines the management of IPMN cases. It also looks into guidelines for managing IPMN and potential risk factors that might increase cancer risk.
- Who can participate: Adults aged 18 to 90 years old with a cystic mass consistent with IPMN on imaging can participate. Those who decline enrollment are excluded.
- Study details: Participants will undergo evaluations to track the progression of IPMN to pancreatic cancer. A placebo is not mentioned in this study.